Crossmark

PROCC: a predictive score to identify KRAS wild type metastatic colorectal cancer patients who are likely to obtain survival benefit from panitumumab treatment

Crossref DOI link: https://doi.org/10.1038/s41416-025-03157-4

Published Online: 2025-08-20

Published Print: 2025-11-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Galmarini, Carlos María https://orcid.org/0000-0001-5494-6617
Zamora, Rafael

Gómez del Campo, Pablo https://orcid.org/0009-0004-6398-1296
del Castillo-Izquierdo, José

De All, José Antonio

Domínguez, Juan Manuel https://orcid.org/0000-0001-9472-6969
License Information

Text and Data Mining valid from 2025-08-20

Version of Record valid from 2025-08-20
More Information

Article History

Received: 5 March 2025

Revised: 4 July 2025

Accepted: 5 August 2025

First Online: 20 August 2025

Competing interests

: CMG is a shareholder and employee of Topazium. JADA is a shareholder and employee of Medicus. RZ is an employee of Medicus. PGC, JC-I and JMD are employees of Topazium.

Document is current

Any future updates will be listed below